The study aimed to describe real-life experience in advanced HCC treatment with SOR at a university hospital in Brazil and to estimate the number of patients with indication of second-line therapy.
Hepatocellular carcinoma Sorafenib is indicated for the treatment of hepatocellular carcinoma (see section 5.1). Renal cell carcinoma Sorafenib is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
Hepatocellular carcinoma Sorafenib Zentiva is indicated for the treatment of hepatocellular carcinoma (see section 5.1). Renal cell carcinoma Sorafenib Zentiva is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
Exelixis, Inc. announced that the FDA approved Cabometyx (cabozantinib) tablets for patients with hepatocellular carcinoma (HCC) who have been previously...
The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin...